CanAssist Breast is a prognostic test that oﬀers insights about tumour
biology, thereby helping oncologists to determine the right treatment regimen
for each patient. The CanAssist Breast risk score determines the patient’s risk
of breast cancer recurrence over five years, allowing patients who are
classified as ‘low-risk’ for breast cancer recurrence to avoid chemotherapy
and its side-eﬀects.
CanAssist Breast aids the doctor in personalizing your cancer treatment plan.
Prognostic tests are now mandated by international treatment guidelines and considered standard of care or “medically necessary” to guide chemotherapy decisions for early stage, hormone receptor-positive breast cancer patients.
Based on a survey of past CanAssist Breast users, major public and private sector health insurance companies have approved claims for reimbursement of CanAssist Breast (TnC apply*).
*T&C: Reimbursement is dependent on the patient’s policy and coverage. OncoStem provides no guarantee that the claim will get approved.